EOC Pharma: Corporate Overview and Pipeline Architecture
Introduction
EOC Pharma (formally operating via eocpharma.com) is an integrated, oncology-focused specialty biopharmaceutical company headquartered in Shanghai, China, with manufacturing and operational complexes located in Taizhou, Jiangsu. Spun out from Eddingpharm in 2015 and led by Chief Executive Officer Dr. Xiaoming Zou, the company is built to operate across the entire drug development lifecycle. EOC Pharma integrates target identification, preclinical discovery, translational medicine, clinical trial design, regulatory registration, manufacturing, and commercialization.
The company's core strategic model relies on a combination of proprietary in-house discovery and strategic in-licensing of globally developed, clinically advanced oncology products. By optimizing these assets specifically for the Chinese regulatory framework and healthcare infrastructure, EOC Pharma aims to provide first-in-class and best-in-class therapies to address unmet needs in solid tumors, hematological malignancies, and precision oncology.
Continue…Core Services and Operational Capabilities
EOC Pharma utilizes a vertically integrated structure to fast-track therapeutic molecules from bench to commercial scale. The company operates distinct functional units:
1. Drug Discovery and Pipeline Enrichment
The drug discovery engine focuses on identifying novel targets and innovative drug modalities displaying superior combinatorial efficacy or distinct mechanisms of action (MoA). The company currently manages multiple pre-clinical candidates, bridging targeted small molecules and therapeutic biologics to synergize with its established clinical-stage portfolio.
2. Clinical Development and Trial Execution
EOC Pharma designs and administers complex clinical protocols within Greater China. This division maintains full ownership over:
* Medical monitoring and investigator selection.
* Patient inclusion and exclusion criteria optimization.
* Primary and secondary endpoint determination for Phase I through Phase III registration studies.
* Translational precision medicine to map biomarker-selected patient populations.
3. Regulatory Affairs and Registration
The company possesses dedicated regulatory teams navigating the National Medical Products Administration (NMPA) framework in China. This division manages Investigational New Drug (IND) filings, clinical trial applications, and New Drug Applications (NDA), maintaining a successful track record of translating foreign clinical dossiers into compliant domestic submissions.
4. Advanced Pharmaceutical Manufacturing
Operating via specialized manufacturing installations in Taizhou, China, the company provides current Good Manufacturing Practice (cGMP) production services. The facility supports clinical trial drug supply, scale-up synthesis, formulation engineering (including solid oral dosage forms and sterile liquid formulations), and commercial product packaging.
5. Sales, Academic Promotion, and Commercialization
The commercial division leverages a robust regional distribution network and specialized oncology sales forces. EOC Pharma conducts target-market academic promotion, medical education campaigns, and manages sales agency collaborations to accelerate penetration into China's expanding oncology market.
Therapeutic Products and Pipeline Architecture
EOC Pharma's therapeutic portfolio comprises precision small-molecule inhibitors and immunotherapies targeted at major cancer indications, including breast cancer, gastric cancer, and rare sarcomas. Key assets in the clinical pipeline include:
1. Efti (Eftilagimod Alpha / EOC202)
Licensed exclusively for the Greater China market from Immutep, Efti is a soluble LAG-3 (lymphocyte activation gene-3) protein and an immune-oncology activator.
* Mechanism: It acts as an antigen-presenting cell (APC) activator designed to stimulate T-cell responses against tumor matrices.
* Target Indication: Evaluated primarily in advanced clinical trials (such as the EOC202A1101 study conducted at the Fudan University Shanghai Cancer Center) for patients with metastatic breast carcinoma.
2. ABI-009 (FYARRO / Sirolimus Albumin-Bound Nanoparticles)
In-licensed via an exclusive collaboration agreement with Aadi Bioscience, EOC Pharma owns the development and commercialization rights for ABI-009 across Greater China.
* Mechanism: An injectable, human albumin-bound nanoparticle formulation of sirolimus, operating as an mTOR (mechanistic target of rapamycin) pathway inhibitor. This formulation achieves significantly higher tumor accumulation and tissue penetration than traditional mTOR inhibitors.
* Target Indication: Developed for advanced malignant PEComa (perivascular epithelioid cell tumor) harboring mutations in the tumor-suppressor genes TSC1 and TSC2, alongside other biomarker-selected solid tumors.
3. Entinostat (EOC102)
In-licensed from Syndax Pharmaceuticals, Entinostat is an orally bioavailable small molecule.
* Mechanism: A class I selective histone deacetylase (HDAC) inhibitor that alters epigenetic transcription within tumor cells and decreases the activity of myeloid-derived suppressor cells (MDSCs).
* Target Indication: Advanced clinical testing for hormone receptor-positive, HER2-negative advanced or metastatic breast cancer, used in combination with hormonal treatments like Exemestane.
